Intravenous immunoglobulin (IVIG) promotes brain repair and improves cognitive outcomes after traumatic brain injury in a FcγRIIB receptor-dependent manner
Copyright © 2022 Elsevier Inc. All rights reserved..
Intravenous immunoglobulin (IVIG) is a promising immune-modulatory therapy for limiting harmful inflammation and associated secondary tissue loss in neurotrauma. Here, we show that IVIG therapy attenuates spatial learning and memory deficits following a controlled cortical impact mouse model of traumatic brain injury (TBI). These improvements in cognitive outcomes were associated with increased neuronal survival, an overall reduction in brain tissue loss, and a greater preservation of neural connectivity. Furthermore, we demonstrate that the presence of the main inhibitory FcγRIIB receptor is required for the beneficial effects of IVIG treatment in TBI, with our results simultaneously highlighting the role of this receptor in reducing secondary damage arising from brain injury.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:109 |
|---|---|
| Enthalten in: |
Brain, behavior, and immunity - 109(2023) vom: 15. März, Seite 37-50 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Willis, Emily F [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Immunoglobulins, Intravenous |
|---|
| Anmerkungen: |
Date Completed 15.03.2023 Date Revised 17.03.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.bbi.2022.12.018 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM350926492 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM350926492 | ||
| 003 | DE-627 | ||
| 005 | 20231226050116.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.bbi.2022.12.018 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1169.xml |
| 035 | |a (DE-627)NLM350926492 | ||
| 035 | |a (NLM)36581304 | ||
| 035 | |a (PII)S0889-1591(22)00476-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Willis, Emily F |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Intravenous immunoglobulin (IVIG) promotes brain repair and improves cognitive outcomes after traumatic brain injury in a FcγRIIB receptor-dependent manner |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.03.2023 | ||
| 500 | |a Date Revised 17.03.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Elsevier Inc. All rights reserved. | ||
| 520 | |a Intravenous immunoglobulin (IVIG) is a promising immune-modulatory therapy for limiting harmful inflammation and associated secondary tissue loss in neurotrauma. Here, we show that IVIG therapy attenuates spatial learning and memory deficits following a controlled cortical impact mouse model of traumatic brain injury (TBI). These improvements in cognitive outcomes were associated with increased neuronal survival, an overall reduction in brain tissue loss, and a greater preservation of neural connectivity. Furthermore, we demonstrate that the presence of the main inhibitory FcγRIIB receptor is required for the beneficial effects of IVIG treatment in TBI, with our results simultaneously highlighting the role of this receptor in reducing secondary damage arising from brain injury | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Immunoglobulins, Intravenous |2 NLM | |
| 700 | 1 | |a Gillespie, Ellen R |e verfasserin |4 aut | |
| 700 | 1 | |a Guse, Kirsten |e verfasserin |4 aut | |
| 700 | 1 | |a Zuercher, Adrian W |e verfasserin |4 aut | |
| 700 | 1 | |a Käsermann, Fabian |e verfasserin |4 aut | |
| 700 | 1 | |a Ruitenberg, Marc J |e verfasserin |4 aut | |
| 700 | 1 | |a Vukovic, Jana |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Brain, behavior, and immunity |d 1992 |g 109(2023) vom: 15. März, Seite 37-50 |w (DE-627)NLM012962538 |x 1090-2139 |7 nnns |
| 773 | 1 | 8 | |g volume:109 |g year:2023 |g day:15 |g month:03 |g pages:37-50 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.bbi.2022.12.018 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 109 |j 2023 |b 15 |c 03 |h 37-50 | ||